A woman with dangerously high cholesterol has been getting an injection every few weeks for years — and it’s effective, but another needle to deal with on top of everything else. Starting this week, patients like her have a new option: the same type of cholesterol-lowering treatment, but as a pill a day instead of an injection.
On July 16, 2026, the US Food and Drug Administration approved Merck’s drug Lefendra (enlycitide), making it the first oral PCSK9 inhibitor approved for use in the United States. It’s a truly new class of pill, not just another statin, arriving to treat a condition that affects a large percentage of American adults.
Key takeaways
- Lipfendra is the first pill version of a PCSK9 inhibitor, a class of cholesterol medications previously available only as an injection.
- In clinical trials, it reduced bad LDL cholesterol by 56-59% compared to placebo, as well as any statin the patient was already taking.
- It’s approved for adults with high cholesterol, including a genetic form called heterozygous familial hypercholesterolemia (HeFH).
- Side effects were generally similar to placebo, although some patients experienced diarrhea or dizziness.
- Lepfendra itself has not yet been shown to reduce heart attacks or strokes, and this data is still being collected in an ongoing trial.
Why pill version matters
About one in four American adults has it High LDL cholesterola major driver of heart attacks and Strokes. Statins are the usual first-line treatment, but some people don’t get enough benefit from statins alone, can’t tolerate them, or have a genetic condition like HeFH that keeps their cholesterol high regardless. For these patients, injectable PCSK9 inhibitors, such as Repatha and Praluent, have been available for about a decade and work by blocking a protein (PCSK9) that may interfere with the liver’s ability to remove cholesterol from the blood. Lepfendra uses the same mechanism, but Merck built it as a small, circular molecule (called a macrocyclic peptide) that can survive digestion and can be taken as a pill — a technical hurdle that has kept this type of drug injection only until now.
What experiments have shown
The approval was based on two phase III trials involving thousands of patients. In the larger trial, Lepfendra lowered bad LDL cholesterol by 56% more than placebo after 24 weeks, in addition to any medication patients were already taking on a statin; In patients with hereditary hypercholesterolemia (HeFH), the reduction was 59%. Side effects were similar in frequency to placebo overall, although HeFH patients reported diarrhea (7%) and dizziness (9%) at somewhat higher rates. Adherence to the trials was remarkably high, with 97% of participants taking all or nearly all of their prescribed doses, likely helped by the simplicity of taking daily pills compared to periodic injections.
What remains unproven
It pays to be precise about what this consent shows and what it does not show. Lipfendra apparently lowers LDL cholesterol – that’s what it got approved for. What has not been directly proven yet is whether taking Lipfendra itself reduces a patient’s risk of actually developing the disease heart attack Or stroke, rather than just improving your blood test number. Merck has a separate outcomes trial underway to answer this question, although LDL lowering itself has a long track record of translating into fewer cardiovascular events with other drugs in the same class. It’s also worth noting that PCSK9 inhibitors as a class have not sold as well as originally expected since the launch of injectable versions a decade ago, so it remains to be seen how quickly these pills will be adopted — and how much they will cost patients.
What comes next?
Lipfendra was approved through the FDA Commissioner’s National Priority Voucher Program, a newer pathway designed to speed up review of certain drugs, and Merck said it is working to get the drug to patients quickly. It also outperforms AstraZeneca’s rival PCSK9 oral tablet in the market, so more competition in this space may follow.
Source: FDA, “FDA Approves First Oral Therapy That Blocks PCSK9 to Lower Bad Cholesterol in Adults with High Cholesterol,” July 16, 2026; LIPFENDRA (enlicitide) approval announcement from Merck, July 2026.
